Eli Lilly beats on earnings even

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance
Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly formally reports its quarterly
Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before
Eli Lilly reports mixed earnings, increases 2025 guidance
Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street estimates and sending its stock up about 2% in pre-market trad
Eli Lilly annual profit outlook tops expectations; stock gains
Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as the drugmaker targets expansion of its weight-loss treatments, sending shares higher. At 10:59 AM ET, Eli Lilly's stock was up 3.2%.
Eli Lilly and Company (LLY) Projected to Post Earnings on Thursday
Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $5.
Eli Lilly And Co. Q4 Profit Increases, Beats Estimates
Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The
Eli Lilly (LLY) Q4 Earnings and Revenues Top Estimates
Eli Lilly (LLY) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $2.49 per share a year ago. These figures are adjusted for non-recurring items.
Eli Lilly and Company (NYSE:LLY) Shares Up 0.1% on Analyst Upgrade
Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 0.1% during mid-day trading on Monday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist Financial currently has a buy rating on the stock.
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds Expectations
Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint came in 1% above analysts’ estimates.
Why Eli Lilly Stock Popped on Thursday
Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...
Seeking Alpha6d
LLY Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...